Background
This derivative action arises from a control contest over Aurion Biotech between two rival Series C investors: Alcon Research, LLC (36% ownership) and Deerfield Private Design Fund V, L.P. (50% ownership). Both investors held board designee rights under a voting agreement. In June 2024, the board’s Special Committee authorized pursuit of an IPO; Alcon’s then-designee voted against it. Alcon subsequently sued, arguing the company needed 66.7% Series C approval to proceed. On January 27, 2025, this court ruled Aurion could pursue the IPO but that Alcon could revoke its voting proxy agreement.
On February 6, 2025, the Special Committee voted to postpone the IPO pending audited financials. Six days later, Alcon purchased Series B stock from Petrichor, becoming the controlling shareholder with 54% ownership. On February 16, Alcon removed Petrichor’s board designee and installed its own designee Bankes, giving Alcon control of three of six board seats. Deerfield subsequently sued; the parties settled in March 2025, with Alcon buying out Deerfield’s entire stake for 99% ownership. David Rostov, a former CFO and co-founder holding common stock, objected to the settlement and filed this derivative action against the directors and stockholder-defendants.
The Court’s Holding
The court granted defendants’ motion to dismiss all six counts. On the Controller Claim (breach of fiduciary duty by Alcon and Petrichor), the court found fatal the fact that the IPO had already been postponed by the disinterested Special Committee on February 6, before Alcon became a controlling stockholder and before any of the challenged February Actions. Plaintiff failed to allege facts showing the postponed IPO was so clearly beneficial that blocking it would constitute a breach, nor did he allege that defendants objected to some future IPO or that inaction on an already-postponed transaction constitutes breach.
On the Director Claim against individual board members, the court held that Plaintiff engaged in impermissible “group pleading”—alleging conduct against directors as a class rather than pleading bad faith against each individual director. Because directors were protected by an exculpatory charter provision, Plaintiff bore the burden of pleading bad faith facts; a single statement by Bankes using the plural pronoun “we” was insufficient. The claim also failed because it rested on board inaction regarding a postponed IPO, not affirmative misconduct, and Delaware law presumes directors act in good faith and applies business judgment deference to strategic decisions.
On the Frinzi Claim (breach by board chair’s resignation), the court found Frinzi’s resignation did not rise to the level of extreme circumstances recognized in Puda Coal, where directors had resigned to obstruct derivative claims against a CEO for theft. Directors have a general right to resign without incurring fiduciary liability absent unusual circumstances. On the Settlement Claim, the court found Deerfield could not have breached fiduciary duties by settling Aurion II because the derivative claims were dismissed without prejudice, so no prejudicial control premium could have been extracted from their dismissal. The court also noted Plaintiff’s own allegations contradicted the theory that Alcon was a controller at the time of settlement. On the Entire Fairness Claim, the court again noted the IPO was postponed before Alcon’s challenged conduct and found no facts supporting unfairness of the amended convertible notes beyond conclusory assertions about hypothetical better financing terms. Finally, on the Right-of-First-Refusal Claim, the court held that Schedule B of the Right of First Refusal Agreement—which listed the “Key Holders” subject to the agreement—was blank, and despite Petrichor’s and Deerfield’s inclusion as “Investors” in Schedule A, they were not “Key Holders.” Additionally, the transfers involved preferred stock, which the agreement explicitly excludes from “Transfer Stock” subject to the right of first refusal.
Key Takeaways
- A controlling shareholder cannot be held liable for blocking a transaction that was already postponed by a disinterested, independent committee before the shareholder obtained control.
- Stockholder derivative claims alleging breach of fiduciary duty against multiple directors protected by exculpatory provisions must plead bad faith facts against each director individually; group pleading is insufficient.
- Board inaction regarding a postponed strategic initiative does not constitute breach of fiduciary duty absent clear allegations that the postponed transaction was so obviously beneficial that refusing to pursue it violated duties of care or loyalty.
- A director’s right to resign from a board is generally unqualified absent extreme circumstances such as those involving obstruction of derivative suits against wrongdoing executives.
- Contractual interpretation of right-of-first-refusal provisions applies standard canons: blank schedules are controlling, and the last-antecedent rule applies to exclude carve-outs from a definition.
Why It Matters
This decision substantially narrows derivative plaintiffs’ ability to challenge control transactions in the private equity context. By requiring that claims be evaluated against the actual timeline of events—here, dismissing liability for actions taken after an IPO had already been postponed—the court makes clear that plaintiffs cannot retrofit a post-hoc narrative attributing causation to defendant conduct when intervening events or prior independent decisions broke the causal chain. The ruling also reinforces heightened pleading requirements for stockholder claims against exculpated directors, requiring particularized bad-faith allegations for each defendant rather than group accusations of disloyalty.
For counsel representing stockholders and fiduciaries in control contests, the decision underscores the critical importance of establishing that strategic decisions (IPO postponement, board restructuring) resulted from defendant coercion rather than independent judgment, and documenting the timeline meticulously. The court’s interpretation of the Right of First Refusal Agreement—treating blank schedules and standard contractual canons as dispositive—also counsels precision in drafting investor consent agreements and transfer restrictions to avoid future disputes over which parties are bound.